The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research

Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Unfortunately, in an important sense they are the weakest links. This article describes two designs that are being explored today: platform trials and basket trials. Both are attempting to merge clinical research and clinical practice.

[1]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[2]  J. Neyman,et al.  INADMISSIBILITY OF THE USUAL ESTIMATOR FOR THE MEAN OF A MULTIVARIATE NORMAL DISTRIBUTION , 2005 .

[3]  H. Baker.  2013 San Antonio Breast Cancer Symposium. , 2014, The Lancet Oncology.

[4]  D. Berry,et al.  Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL , 2013 .

[5]  Lisa McShane,et al.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[6]  D. Berry,et al.  Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.

[7]  I. Torjesen.  Large personalised medicine trial in lung cancer heralds new research partnership , 2014, BMJ : British Medical Journal.

[8]  D. Berry,et al.  Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials , 2012, Clinical Cancer Research.

[9]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[10]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[11]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[12]  K. Anderson,et al.  The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. , 2011, Cancer discovery.

[13]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[15]  Nathalie Seigneuret,et al.  The Innovative Medicines Initiative: an engine for regulatory science , 2014, Nature Reviews Drug Discovery.

[16]  D. Berry,et al.  Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL , 2014 .

[17]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[18]  Asher Mullard,et al.  Multicompany trials adapt to disciplines beyond cancer , 2014, Nature Medicine.

[19]  C. Stein,et al.  Estimation with Quadratic Loss , 1992 .

[20]  J. Brady,et al.  The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. , 2015, The Journal of the American College of Dentists.